What Pymepharco JSC does

STADA Pymepharco (legal name Pymepharco JSC) is a Vietnamese pharmaceutical manufacturer and distributor, founded in 1989 in Tuy Hòa, Đắk Lắk Province, and operating as the sole Vietnam-based member of Germany's STADA Group since the 2021 acquisition. The company runs two EU-GMP certified factories at a single Đắk Lắk site, with combined annual production capacity of 1.2–1.4 billion units per shift per factory plus 20–40 million finished packaging units annually per facility. Its portfolio in Vietnam comprises 250 generic pharmaceutical products (including 80 validated as bioequivalent to originator/innovator drugs) and 150 consumer healthcare products, marketed under brand identities that include NIZORAL® Cream, Natures Aid, and Walmark. The portfolio positions it among the larger pharmaceutical players in Vietnam by SKU count.

The business model is B2B and B2B2C pharmaceutical distribution through a nationwide direct field sales force, scientific marketing to healthcare professionals via medical seminars and conferences, and channel partnerships through pharmacy chains and pharmaceutical distributors. The company serves three primary customer segments: hospitals and healthcare facilities (procuring generic drugs), pharmacies and pharmacy chains (distributing both Rx generics and OTC healthcare products), and pharmaceutical distribution businesses. Reported reach is 16,000+ customers nationwide. Pricing is quote-based and not publicly disclosed. Contract manufacturing activity also exists within the broader STADA Group network, which markets 25,000 products globally in 100+ countries, derived from approximately 800 APIs.

The company is privately held as a subsidiary of STADA Group (Frankfurt-listed under ticker STA1). It employs approximately 1,000 people across offices, factories, and the nationwide sales force. Strategic emphasis is on applying German/EU-GMP quality standards to locally manufactured Vietnamese generics and consumer healthcare products, supported by a Sustainalytics ESG rating that places the parent in the top 3% of pharmaceutical companies globally. Recent activity indicates continued commercial buildout (distribution partnerships, brand alignment) rather than major capacity or geographic expansion.

Name

Pymepharco JSC

Legal name

Pymepharco JSC

Website

https://pymepharco.com

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

251–500 employees

Short description

STADA Pymepharco (Pymepharco JSC) is a Vietnamese generic pharmaceutical manufacturer, operating two EU-GMP factories in Đắk Lắk since 1989 and serving 16,000+ hospitals, pharmacies, and distributors nationwide as the sole Vietnam subsidiary of Germany's STADA Group.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

Keywords

• Generic pharmaceuticals
• EU-GMP manufacturing
• Consumer healthcare products
• Bioequivalent drugs
• Pharmaceutical distribution

Headquarters

HQ city

Tuy Hòa

HQ country

Vietnam

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Generic Pharmaceutical Drugs: B2B and B2B2C sales of generic pharmaceutical drugs to hospitals, pharmacies, and pharmaceutical distribution businesses across Vietnam. Revenue generated through sale of 250 generic drug products.
2. Healthcare/OTC Products: Over-the-counter healthcare products sold through pharmacy networks. 150 healthcare products in portfolio including Natures Aid, Walmark, and NIZORAL brands.
3. Contract Manufacturing for STADA Group: Manufacturing products as part of the global STADA Group network, contributing to 25,000 products globally with 8,000 healthcare products developed from approximately 800 active pharmaceutical ingredients (APIs).

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Pymepharco JSC (operating as STADA Pymepharco) is a Vietnamese pharmaceutical manufacturer that produces and distributes generic drugs and consumer healthcare products. The company operates two EU-GMP certified factories in Tuy Hòa, Đắk Lắk province, producing 250 generic drugs (including 80 bioequivalent products) and 150 healthcare/OTC products, distributed through hospitals, pharmacies, and pharmaceutical distribution businesses across Vietnam. As the sole member of Germany's STADA Group in Vietnam since 2021, it also handles contract manufacturing for the global STADA network.

Product overview

STADA Pymepharco operates as a pharmaceutical company offering a dual portfolio of Generic Medications (250 products with 80 bioequivalent drugs) and Healthcare/Wellness Products (150 products). The company leverages EU-GMP certified manufacturing capabilities at two factories in Dak Lak, Vietnam, with annual production capacity of 1.2-1.4 billion units per factory. Products are distributed through a network of 16,000+ customers including hospitals, pharmacies, and pharmacy chains across Vietnam, representing one of the largest pharmaceutical portfolios among international and domestic companies in the country.

Differentiator

Problem solved

Functional benefit

Products and services

• Generic Pharmaceutical Drugs
• Healthcare/OTC Products
• NIZORAL® Cream
• Contract Manufacturing Services for STADA Group

Quantifiable outcome

• 80 products evaluated as bioequivalent to originator drugs
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• MBA TalentcoreStrategic or Co-development Partner · 3 July 2026Strategic partnership for developing future leadership team. STADA Pymepharco signed cooperation agreement with MBA Talent to build and develop next-generation leadership capabilities within the organization.
• PharmadicoreChannel Partner/ Reseller/ Distributor · 29 May 2026B2B distribution partnership for Natures Aid and Walmark brands via pharmacy channel in Vietnam. STADA Pymepharco partnered with Pharmadi to distribute health supplement brands through the B2B pharmacy network.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• OPC Pharmaceutical JSC: Vietnamese pharmaceutical manufacturer producing generic drugs and healthcare products. Similar in scale and B2B distribution to hospitals and pharmacies within Vietnam.
• Bidiphar JSC: Vietnam-based pharmaceutical manufacturer with focused on generic and branded pharmaceutical products. Comparable in operating model, target market, and GMP-certified manufacturing.
• DHG Pharmaceutical (Hau Giang Pharmaceutical JSC): Vietnam's largest domestic pharmaceutical manufacturer producing generic drugs and consumer healthcare products. Directly comparable in product portfolio, B2B distribution model, and target customers (hospitals and pharmacies across Vietnam).
• TV.Pharm (Vietnam Pharmaceutical Corporation): Vietnamese state-affiliated pharmaceutical company with generic drug manufacturing and B2B distribution. Comparable in serving hospitals and pharmacies with broad generic portfolios.
• Imexpharm Corporation: Vietnamese generic pharmaceutical manufacturer with GMP-certified factories and a domestic B2B distribution network. Comparable in manufacturing capacity, product portfolio breadth, and target customer segments.
• Traphaco JSC: One of Vietnam's leading traditional and modern pharmaceutical manufacturers with a broad generic and OTC portfolio. Comparable in scale, distribution reach, and sales-led GTM serving hospitals and pharmacies nationwide.

Broad incumbents

• Sandoz (Novartis): Global generic and biosimilar pharmaceutical manufacturer. Comparable in EU-GMP certified manufacturing, broad generic portfolio, and biosimilar/bioequivalent product strategy.
• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with global footprint. Comparable in generic pharmaceutical manufacturing, large product portfolio, and global distribution model.
• STADA Group (Parent): German pharmaceutical company and Pymepharco's parent, operating a global portfolio of 25,000 products across 100+ countries. Relevant as the broader parent entity providing portfolio, APIs, and global brand backing.
• Viatris (formerly Mylan): Global pharmaceutical company producing generic and branded medications with extensive manufacturing footprint. Comparable in generic drug manufacturing scale and international quality standards.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/stadapymepharco
• LinkedInlinkedin.com/company/pymepharco-stada

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pymepharco JSC